OTCMKTS:NWBO - Northwest Biotherapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.29 -0.01 (-3.33 %)
(As of 03/25/2019 04:00 PM ET)
Previous Close$0.2950
Today's Range$0.2841 - $0.30
52-Week Range$0.17 - $0.35
Volume892,152 shs
Average Volume1.02 million shs
Market Capitalization$154.78 million
P/E RatioN/A
Dividend YieldN/A
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Receive NWBO News and Ratings via Email

Sign-up to receive the latest news and ratings for NWBO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:NWBO
Previous SymbolNASDAQ:NWBO



Sales & Book Value

Annual Sales$330,000.00
Book Value($0.20) per share


Net Income$-73,140,000.00
Net Margins-6,258.93%


Market Cap$154.78 million
Next Earnings Date3/29/2019 (Estimated)
OptionableNot Optionable

Northwest Biotherapeutics (OTCMKTS:NWBO) Frequently Asked Questions

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO."

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) announced its earnings results on Monday, August, 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.22. The biotechnology company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.20 million. View Northwest Biotherapeutics' Earnings History.

When is Northwest Biotherapeutics' next earnings date?

Northwest Biotherapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 29th 2019. View Earnings Estimates for Northwest Biotherapeutics.

What price target have analysts set for NWBO?

0 analysts have issued 12 month target prices for Northwest Biotherapeutics' stock. Their predictions range from $0.23 to $0.23. On average, they anticipate Northwest Biotherapeutics' stock price to reach $0.23 in the next twelve months. This suggests that the stock has a possible downside of 20.7%. View Analyst Price Targets for Northwest Biotherapeutics.

Has Northwest Biotherapeutics been receiving favorable news coverage?

News articles about NWBO stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Northwest Biotherapeutics earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future.

Who are some of Northwest Biotherapeutics' key competitors?

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), SLS International (SLS), Amarin (AMRN), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Keryx Biopharmaceuticals (KERX), Avid Bioservices (CDMO) and Immunomedics (IMMU).

Who are Northwest Biotherapeutics' key executives?

Northwest Biotherapeutics' management team includes the folowing people:
  • Ms. Linda F. Powers J.D., Chairperson, CEO, Pres & CFO (Age 63)
  • Dr. Alton L. Boynton, Founder, Chief Scientific Officer, Sec. & Director (Age 74)
  • Dr. Marnix L. Bosch M.B.A., Ph.D., MBA, Chief Technical Officer (Age 60)
  • Mr. Leslie J. Goldman, Sr. VP & Gen. Counsel (Age 74)
  • Ms. Susan Goldman, Director of Patient Affairs

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Northwest Biotherapeutics' stock price today?

One share of NWBO stock can currently be purchased for approximately $0.29.

How big of a company is Northwest Biotherapeutics?

Northwest Biotherapeutics has a market capitalization of $154.78 million and generates $330,000.00 in revenue each year.

What is Northwest Biotherapeutics' official website?

The official website for Northwest Biotherapeutics is http://www.nwbio.com.

How can I contact Northwest Biotherapeutics?

Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The biotechnology company can be reached via phone at 240-497-9024 or via email at [email protected]

MarketBeat Community Rating for Northwest Biotherapeutics (OTCMKTS NWBO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about Northwest Biotherapeutics and other stocks. Vote "Outperform" if you believe NWBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Featured Article: Straddles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel